New hope for immunotherapy side effects: which drug works best for colitis?
NCT ID NCT04407247
First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This study compares two medications, infliximab and vedolizumab, to treat colitis (colon inflammation) caused by immune checkpoint inhibitor therapy in cancer patients. About 47 adults with genitourinary cancer, melanoma, or non-small cell lung cancer are participating. The goal is to see which drug works better to control this side effect and help patients recover.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Can a new PET tracer reveal hidden immune clues in tumors?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Can a modified herpes virus turn the tide against advanced cancer?